Cellular Mechanisms (CM) is a new research program in the Masonic Cancer Center (MCC) formed when the Cell Signaling and Tumor Microenvironment Programs merged into one highly integrated program to strengthen the science of cellular mechanisms of cancer and expand opportunities for translation of research discoveries into new therapeutic modalities. The Program?s goal is to identify biological mechanisms that drive cancer development, tumor progression, and metastasis, including therapy-resistant recurrence, and then develop novel targeted therapies. The 3 integrated Aims are 1) to identify oncogenic signaling pathways within and between diverse cells in tumors that can be targeted to limit tumor growth, invasion, and metastasis; 2) to define epigenetic events in tumor transcriptomes that enhance malignancy or resistance to therapy; 3) to determine how tumors cause protumorigenic changes in the associated stroma and how ?cancerized? stroma and tumor-reactive host cells impact tumor progression, invasion, migration, and metastasis. The Program is co-led by Drs. Carol Lange and James McCarthy and has 45 members, representing 19 departments and 8 schools or colleges. For the last budget year, CM members were supported by $4.8 million in direct costs from the National Cancer Institute; cancer-focused, sponsored funding from all sources totaled over $10.7 million (direct costs). Since 2013, CM members have published 1027 papers, 8% of which resulted from intraprogrammatic collaborations, 22% from interprogrammatic collaborations, and 82% from external collaborations; 89 were published in journals with an impact score of 10 or higher. Since 2013, 221 clinical trials across all clinical research categories have opened under this programmatic area and have accrued 1132 subjects. The MCC has provided substantial value to the program, including recruitment of 5 new faculty and funding of $1.08M in pilot projects that have led to over $5.5 million in externally funded grants. CM members use all 10 MCC Shared Resources. In addition, the MCC was instrumental in supporting the 2nd annual Regional Midwest Tumor Microenvironment Meeting in May of 2015, which hosted 132 attendees from 7 academic institutions. Members of this well-integrated interdisciplinary Program bring complimentary expertise to identifying how tumor and host cell interactions impact tumor progression, elucidating the complexities of metastatic and hormone-refractory disease, and determining how deregulation of signaling inputs to transcriptional control might be exploited to improve therapy. The study of targetable factors related to stroma remodeling and fibrosis is also a research strength. Novel therapies are being developed using antibodies, recombinant toxins, small molecules, and medicinal chemistry/fragment-based drug design to target signaling pathways and alter tumor metabolism. Program members have substantial interactions with the Immunology and Genetic Mechanisms Programs. The CM Program fulfills key components of the Cellular and Molecular Therapeutics and Biomarker Discovery (SPG1 and SPG4) MCC Strategic Scientific Priorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-23
Application #
10086448
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1998-06-01
Project End
2024-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
23
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Lin, Lifeng; Chu, Haitao; Murad, Mohammad Hassan et al. (2018) Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med 33:1260-1267
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Hupp, Meghan; Williams, Sarah; Dunnette, Brian et al. (2018) Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas. Hum Pathol :
Rashidi, Armin; Shanley, Ryan; Holtan, Shernan G et al. (2018) Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:2190-2196
Ma, Bin; Zarth, Adam T; Carlson, Erik S et al. (2018) Methyl DNA Phosphate Adduct Formation in Rats Treated Chronically with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of Its Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 31:48-57
Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A et al. (2018) Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 320:880-891
Lee, Hak Rae; Leslie, Faith; Azarin, Samira M (2018) A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2. J Biol Eng 12:12
Yang, Libang; Herrera, Jeremy; Gilbertsen, Adam et al. (2018) IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. Am J Physiol Lung Cell Mol Physiol 314:L127-L136

Showing the most recent 10 out of 1013 publications